[1] Martin P, Lau TY, Nguyen MH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2015 Update. Clin Gastroenterol Hepatol,2015,13: 2071-2087.e16.
[2] Iloeje UH, Yang H, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology, 2006, 130:678-686.
[3] Lok ASF. Chronic hepatitis B.Hepatology, 2007, 45:507-539.
[4] Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA Level. JAMA, 2006, 295: 65-73.
[5] Doong SL, Tsai CH, Schinazi RF, et al. Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues.Proc Natl Acad Sci USA,1991, 88:8495-8499.
[6] Fabien Z. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection.Antiviral Res, 2004, 64:1-15.
[7] Locarnini S. Molecular virology and the development of resistant mutants: implications for therapy.Semin Liver Dis, 2005, 25 Suppl 1:9-19.
[8] Locarnini S.Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure. Hepatol Int,2008, 2: 147-151.
[9] Lok AS, Zoulim F, Locarnini S, et al. Antiviral drug-resistant HBV: standardization of omenclature and assays and recommendations for management.Hepatology,2007,46: 254-265.
[10] 卢明辉. 核苷类药物抗病毒耐药分析. 医学信息, 2014,11:217-218.
[11] 李玉芳. 核苷(酸)类似物抗乙型肝炎病毒治疗耐药的处理. 临床内科杂志, 2013, 30:734-736.
[12] 徐丙发,范清林,魏伟,等. 干扰素-α及长效干扰素抗肝炎病毒作用机制的研究进展. 中国药理学通报, 2008, 24:1276-1279.
[13] Leemans WF, Flink HJ, Janssen HL, et al. The effect of pegylated interferon-alpha on the treatment of lamivudine resistant chronic HBeAg positive hepatitis Bvirus infection. J Hepatol, 2006, 44:507-511.
[14] Malathi K, Paranjape JM, Bulanova E, et al. A transcriptional signaling pathway in the IFNsystem mediated by 2′-5′-oligoadenylate activation of RNase L. Proc Natl Acad Sci U S A, 2005:14533-14538.
[15] 郭远, 陈从新. α-干扰素治疗慢性乙型肝炎疗效预测因素研究进展. 实用肝脏病杂志, 2015:558-562.
[16] Buster EH, Hansen BE, Lau GK et al. Factors That Predict Response of Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B to Peginterferon-Alfa.Gastroenterology, 2009, 137: 2002-2009.
[17] 黄芳, 龚环宇, 鲁猛厚. 聚乙二醇干扰素治疗HBeAg阳性慢性乙型肝炎患者外周血NKT细胞的变化及疗效预测. 中国感染控制杂志, 2013, 12:88-91.
[18] Sonneveld MJ, Vincent R, Yilmaz C, et al. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α 2b: relation to response and HBV genotype. Antivir Ther, 2012, 17:9-17.
[19] 高国生, 徐晓珍, 胡耀仁,等. 乙型肝炎病毒基因型与聚乙二醇干扰素α治疗HBeAg阳性慢性乙型肝炎疗效的关系. 中华内科杂志, 2013, 52:920-923.
[20] Lau GK. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med, 2005, 352:2682-2695.
[21] Sprinzl MF, Kittner JM, Russo C, et al. Add-on Interferon-a therapy increases HBV specific T cell responses in patients with chronic hepatitis B under efficient antiviral nucleot(s)ide therapy. Hepatology, 2012, 56(4 Suppl):1058A.
[22] 金怡, 黄春洋, 魏飞力,等. 联合治疗策略在应答不佳/耐药HBeAg阳性慢性乙型肝炎患者中的临床研究. 传染病信息, 2015:273-278.
[23] 林琪, 余雪平, 苏智军,等. 核苷(酸)类似物治疗慢性乙型肝炎部分应答后加用α干扰素继续治疗疗效分析. 实用肝脏病杂志, 2013, 16:232-234.
[24] 金瑞, 郭新会, 徐志强,等. IFN-α 1b治疗核苷(酸)类似物经治未达满意终点的CHB多中心疗效分析. 中国肝脏病杂志:电子版, 2014:63-67.
[25] 丁艾昆, 郭利伟, 欧阳瑞春,等. 聚乙二醇干扰素a-2a联合核苷(酸)类似物治疗HBeAg阳性慢性乙型肝炎的疗效观察. 中国病原生物学杂志, 2015:272-276.
[26] 唐奇远, 何清, 唐情容,等. 长效干扰素序贯恩替卡韦与单用恩替卡韦治疗HBeAg阳性慢性乙型肝炎疗效的比较. 今日药学, 2015:340-342.
[27] 李聪智, 陈莉, 孟秀娟,等. 核苷类药物耐药慢性乙型肝炎的长效干扰素治疗. 第7届全国疑难及重症肝病大会论文集, 2013.
[28] Sun J, Hou JL, Xie Q, et al. Randomised clinical trial: efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance. Aliment Pharmacol Ther, 2011, 34:424-431.
[29] Wiegand J, Hasenclever D, Tillmann HL. Should treatment of hepatitis B depend on hepatitis B virus genotypes A hypothesis generated from an explorative analysis of published evidence. Antivir Ther, 2008, 13:211-220.
[30] Erhardt A, Blondin D, Hauck K, et al. Response to interferon alfa is HBV genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut, 2005, 54:1009-1013.
[31] Sonneveld MJ, Rijckborst V, Boucher CA,et al. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology, 2010; 52: 1251-1257.
[32] Sonneveld MJ, Vincent R, Stefan Z, et al. Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B. Hepatology, 2012, 56:67-75.
[33] Ofliver EAF. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection.J Hepatol, 2011, 55:245-264.
[34] 纪永健, 李菲菲, 任万华,等. HBeAg早期下降对聚乙二醇干扰素α-2a治疗HBeAg阳性慢性乙型肝炎的疗效预测. 山东大学, 2013.
[35] Chen XY, Cao ZH, Liu YL, et al. Potent hepatitis B surface antigen response to treatment of hepatitis-B-e-antigen-positive chronic hepatitis B with α-interferon plus a nucleos(t)ide analog. J Gastroenterol Hepatol, 2012, 27:481-486. |
